Abstract: [Problem] To provide a urine scattering prevention device which does not give off a foul smell even when used, and which is easy to replace. [Solution] A urine scattering prevention device 1 includes a urine receiving portion 5 disposed in a urinal 3, and a leg portion 7 which supports the urine receiving portion 5 vertically upward.

Abstract: [Problem] To enable a person intended by a chairperson to be effectively determined as a speaker by matching the hand-raising of the speaker and an indicating direction of the chairperson, and turning ON only a microphone of the matched speaker. [Solution] Provided is a conference support system including: a plurality of voice input means which receive voices as an input; a plurality of ON/OFF control means which control the plurality of voice input means to be respectively turned ON/OFF and which respectively correspond to the plurality of voice input means; a hand-raising recognition means which recognizes hand-raising positions of participants, which respectively corresponds to the plurality of voice input means; a designated direction recognition means which recognizes a direction designated by a specified person.

Abstract: [Problem] To provide an enclosure that can be easily cleaned, [Solution] A fish-breeding enclosure including: a frame 3 constituting the sides of a cuboid; a first net 11 covering a right side surface 5, a bottom surface 7, and a left side surface 9 of the frame 3; a first net feeder 19 for feeding the first net 11 and a second net 17 that covers a front surface 13, the bottom surface 7, and a rear surface 15 of the frame 3; and a second net feeder 21 for feeding the second net 17. When the first net 11 or the second net 17 is renewed. the first net 11 or the second net 17 is drawn out from the first net feeder 19 or the second net feeder 21, respectively.

Abstract: To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. This micro-encapsulated aquaculture feed includes: an oil phase 11 having an oil-soluble nutrient component; a water phase 13 which is present inside the oil phase 11, and which includes a water-soluble nutrient component; and a film 15 which includes the oil phase 11 and the water phase 13. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.

Abstract: Anguilliformes breeding water contains a thyroid hormone such as thyroxine, and a method for rearing anguilliformes includes a step for administering a thyroid hormone such as thyroxine, wherein the amount of the thyroid hormone to be administered changes as the anguilliforme fingerling changes from a transformation start phase (stage 1) to a transformation final phase (stage 2), and the amount of the thyroid hormone to be administered in the transformation final phase (stage 2) is less than the amount of the thyroid hormone to be administered in the transformation start phase (stage 1).

Abstract: To provide a method for producing brassieres that can prevent sagging of breasts, achieve effortless bust uplift, and immobilize the breasts when prone. A brassiere production method comprising a step for determining the shape of a region that comprises a breast (15) of a subject (11) when a nipple (13) of the subject (11) is turned vertically downward. An example of the state in which a nipple (13) is turned vertically downward is a state in which the subject is immobilized on a loading table (21) and, compared to the subject's nipple (13), the subject's back is in the direction of the loading table.

Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.

Abstract: Problem To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. Solution An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.

Abstract: [Subject] A test substance application system for animal experiment capable of administering a required amount of a test substance uniformly and reliably from a nose or a mouth into a nasal cavity or into a lung of an experimental animal is provided. [Means for Solution] The system includes a respiration monitoring device 2 that monitors a respiration state of an experimental animal detected by a respiration pick-up device 1 to thereby measure a timing upon switching from an expiratory phase to an inhalatory phase and outputs a trigger signal T at that timing, and an application device 3 that sprays a predetermined amount of a test substance into a nasal cavity or an oral cavity of the experimental animal when the trigger signal T is outputted from the device 2.

Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.

Abstract: Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3? end and 5? end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.

Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.

Abstract: To provide a feed that does not pollute rearing water, improves the immunity activity of leptocephalus larvae, is capable of directly feeding eel leptocephalus, and is capable of effectively inducing the growth of said larvae into glass eels. This micro-encapsulated aquaculture feed includes: an oil phase 11 having an oil-soluble nutrient component; a water phase 13 which is present inside the oil phase 11, and which includes a water-soluble nutrient component; and a film 15 which includes the oil phase 11 and the water phase 13. The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins.

Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.

Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.

Abstract: An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.

Abstract: Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3? end and 5? end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.

Abstract: When a primate is t restrained by a movable partition wall, friction with vertical bars of a lattice of the partition wall causing damages on roots of limbs of the primate is alleviated to reduce or solve such damages. In a primate restraint device comprising a containing body having both side surfaces, a top surface and a bottom surface, a rear surface door capable of opening and shutting the rear surface side of the containing body, and a partition wall formed movably frontward and rearward in the containing body and capable of being fixed at a desired position in the containing body, some sites among vertical bar members of the partition wall, with which roots of limbs of the primate are brought into contact while the limbs are forced to protrude frontward and restrained, are covered with protective cylinders which are rotatable with respect to the vertical bar members.

Abstract: A primate restraint device capable of restricting the movement of a monkey and, particularly, capable of facilitating injection or blood collection. A primate restraint device comprising: a containing body having both side surfaces, a top surface, and a bottom surface; a door provided to the rear surface side of the containing body and capable of opening and closing the rear surface side of the containing body by sliding up and down; and a partition wall which is formed so as to close the inside of the containing body from the front surface side and to be movable forward and backward within the containing body and which is configured to be able to be affixed at a desired position within the containing body. The partition wall has provided therein hind-limb protrusion openings from which the hind limbs of the contained primate are caused to protrude to the outside.

Abstract: Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed.